Oculis Holding AG

OCS

Healthcare|Biotechnology|CH

$7.49

+0.66 (+9.66%)

DCF Value

$1.82

Tangible Book / Share

$3.39

Cash / Share

$0.00

Next Earnings Report

Mar 2, 2027

EPS est. -$0.50 · Revenue est. $300.1K

Financing Filings (last 12 months)

Shelf registrations / offering prospectuses — latest Nov 3, 2026 (424B5). Possible dilution.

Upcoming Data Readouts (2)

Dec 2026

Est. completion

P2P3Dry Eye Disease (DED)

A Clinical Study Evaluating Licaminlimab for Dry Eye Disease

NCT07548632n=160

Dec 2027

Est. completion

P3Optic Neuritis

Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research

NCT07623668n=210

Awaiting Results (1)

Trials past primary completion date but still active — data readout may be imminent.

Oct 2026

Multicenter Study on the Efficacy and Safety of OCS-01 in Subjects With Uveitis Related and Post Surgical Macular Edema

NCT05608837

Recent Press Releases

Oculis Reports Q3 2026 Financial Results and Builds Momentum Toward Multiple Upcoming Pipeline Catalysts

Nov 3, 2026 · GlobeNewsWire

Oculis Appoints Experienced Life Sciences Leader Björn Tackenberg, M.D., Ph.D., as Chief Scientific Officer to Advance Neurology Innovation

Nov 2, 2026 · GlobeNewsWire

Oculis to Feature Privosegtor’s Neuroprotective Potential and Ongoing PIONEER Program at APOIS Congress and CNS Summit

Oct 29, 2026 · Globe News Wire

Oculis to Feature Privosegtor's Neuroprotective Potential and Ongoing PIONEER Program at APOIS Congress and CNS Summit

Oct 29, 2026 · GlobeNewsWire

Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor's Neuroprotective Potential in Optic Neuritis

Oct 22, 2026 · GlobeNewsWire

Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor's Neuroprotective Potential in Optic Neuritis

Oct 22, 2026 · GlobeNewsWire

Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting

Oct 20, 2026 · GlobeNewsWire

Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting

Oct 20, 2026 · Globe News Wire

Oculis lýkur slembiröðun í PREDICT-1 skráningarrannsókninni á Licaminlimab við TNFR1-miðluðum augnþurrki

Oct 19, 2026 · GlobeNewsWire

Oculis Completes Randomization in PREDICT-1 Registrational Trial of Licaminlimab for TNFR1-Mediated Dry Eye Disease

Oct 19, 2026 · GlobeNewsWire

SEC Filings (45)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

Filed	Form	What it is	Links
Nov 3, 2026	424B5	Offering prospectus	Document Index
Nov 3, 2026	6-K	Foreign issuer report	Document Index
Sep 30, 2026	6-K	Foreign issuer report	Document Index
Aug 10, 2026	6-K	Foreign issuer report	Document Index
Aug 6, 2026	S-8	Employee stock plan	Document Index
Aug 6, 2026	6-K	Foreign issuer report	Document Index
Jun 25, 2026	6-K	Foreign issuer report	Document Index
Jun 1, 2026	6-K	Foreign issuer report	Document Index
May 14, 2026	6-K	Foreign issuer report	Document Index
May 11, 2026	6-K	Foreign issuer report	Document Index
Apr 29, 2026	SC 13G/A	Passive 5%+ stake	Document Index
Apr 21, 2026	6-K	Foreign issuer report	Document Index
Mar 27, 2026	SC 13G/A	Passive 5%+ stake	Document Index
Mar 4, 2026	6-K	Foreign issuer report	Document Index
Mar 4, 2026	F-3ASR	Shelf registration	Document Index
Mar 4, 2026	20-F	Annual report (foreign)	Document Index
Mar 3, 2026	6-K	Foreign issuer report	Document Index
Dec 8, 2025	EFFECT		Document Index
Dec 5, 2025	POS AM		Document Index
Dec 1, 2025	424B3	Offering prospectus	Document Index
Nov 14, 2025	SC 13G/A	Passive 5%+ stake	Document Index
Nov 10, 2025	F-3	Shelf registration	Document Index
Nov 10, 2025	6-K	Foreign issuer report	Document Index
Oct 31, 2025	424B5	Offering prospectus	Document Index
Oct 31, 2025	424B5	Offering prospectus	Document Index
Oct 31, 2025	6-K	Foreign issuer report	Document Index
Oct 29, 2025	6-K	Foreign issuer report	Document Index
Oct 6, 2025	6-K	Foreign issuer report	Document Index
Aug 21, 2025	6-K	Foreign issuer report	Document Index
Aug 1, 2025	6-K	Foreign issuer report	Document Index
Jun 5, 2025	S-8	Employee stock plan	Document Index
Jun 5, 2025	6-K	Foreign issuer report	Document Index
May 9, 2025	6-K	Foreign issuer report	Document Index
May 8, 2025	6-K	Foreign issuer report	Document Index
Apr 15, 2025	6-K	Foreign issuer report	Document Index
Mar 11, 2025	20-F	Annual report (foreign)	Document Index
Mar 11, 2025	6-K	Foreign issuer report	Document Index
Feb 14, 2025	6-K	Foreign issuer report	Document Index
Feb 14, 2025	424B5	Offering prospectus	Document Index
Feb 12, 2025	SC 13G/A	Passive 5%+ stake	Document Index